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In traumatic brain injury (TBI) patients, elevation of the brain extracellular lactate
concentration and the lactate/pyruvate ratio are well-recognized, and are associated
statistically with unfavorable clinical outcome. Brain extracellular lactate was
conventionally regarded as a waste product of glucose, when glucose is metabolized
via glycolysis (Embden-Meyerhof-Parnas pathway) to pyruvate, followed by conversion
to lactate by the action of lactate dehydrogenase, and export of lactate into the
extracellular fluid. In TBI, glycolytic lactate is ascribed to hypoxia or mitochondrial
dysfunction, although the precise nature of the latter is incompletely understood.
Seemingly in contrast to lactate’s association with unfavorable outcome is a growing
body of evidence that lactate can be beneficial. The idea that the brain can utilize
lactate by feeding into the tricarboxylic acid (TCA) cycle of neurons, first published two
decades ago, has become known as the astrocyte-neuron lactate shuttle hypothesis.
Direct evidence of brain utilization of lactate was first obtained 5 years ago in a cerebral
microdialysis study in TBI patients, where administration of 13C-labeled lactate via the
microdialysis catheter and simultaneous collection of the emerging microdialysates,
with 13C NMR analysis, revealed 13C labeling in glutamine consistent with lactate
utilization via the TCA cycle. This suggests that where neurons are too damaged to
utilize the lactate produced from glucose by astrocytes, i.e., uncoupling of neuronal
and glial metabolism, high extracellular levels of lactate would accumulate, explaining
the association between high lactate and poor outcome. Recently, an intravenous
exogenous lactate supplementation study in TBI patients revealed evidence for a
beneficial effect judged by surrogate endpoints. Here we review the current state of
knowledge about glycolysis and lactate in TBI, how it can be measured in patients, and
whether it can be modulated to achieve better clinical outcome.
Keywords: traumatic brain injury (human), cerebral energy metabolism, glycolysis, lactate, pyruvate, glucose,
microdialysis
Introduction
Cerebral metabolism following injury appears to differ from that in normal brain, although the full
extent and nature of these changes are poorly understood, especially in man.
Traumatic brain injury (TBI) results from the action of external mechanical forces that cause
macroscopic tissue damage at the time of injury and initiate cellular processes that evolve
over the hours and days that follow. It is a heterogeneous disorder that includes a range
of macroscopic tissue pathologies including hematomas, contusions, and edema. Often these
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lesions are sufficiently large to require urgent surgical evacua-
tion to prevent fatal compression of vital brain structures. Occa-
sionally, even in the presence of severe TBI, defined clinically as
patients presenting in coma, there is little in the way of macro-
scopic damage to the brain evident on CT scans. This illustrates
the impact that pathophysiology at the microscopic level has on
cellular and neurological function. These processes are multifac-
torial and include disturbed ion hemostasis (Unterberg et al.,
2004), excitotoxicity (Katayama et al., 1990; Kawamata et al.,
1992), cell wall and mitochondrial disruption (Xiong et al., 1997;
Lewen et al., 2001), inflammation, and derangements in oxidative
energy metabolism (Jalloh et al., 2014).
Patients with severe TBI frequently have injuries to other parts
of the body such as the lungs or limb bones and are typically man-
aged in an intensive care setting (Chesnut et al., 1993; Stocchetti
et al., 1996). They are medically complex patients with a myr-
iad of attendant issues that need to be considered, for example,
nutrition, respiratory care, and deep-vein thrombosis prophy-
laxis, in addition to complications associated with TBI such as
seizures, hydrocephalus, and endocrine dysfunction. Overall, TBI
is one of the leading causes of mortality and morbidity in young
adults. The most recent large observational studies report unfa-
vorable outcomes from severe TBI ranging between 54 and 66%
(Roozenbeek et al., 2013).
The best-known metabolic characteristics of injured brain are
a high lactate concentration and a high lactate/pyruvate (L/P)
ratio, in the brain extracellular fluid. An L/P ratio greater than
25 is interpreted as arising from high glycolytic activity indica-
tive of hypoxia or mitochondrial dysfunction (Timofeev et al.,
2011a), although the precise nature of the latter is incompletely
understood. A recent study in 233 TBI patients demonstrated
that L/P ratio >25 predicted unfavorable clinical outcome in a
multivariate analysis in addition to previously known predictors
FIGURE 1 | Schematic of the microdialysis catheter tip. Substances in
the extracellular fluid outside the catheter tip are able to diffuse across the
microdialysis membrane to be collected for analysis. Abbreviation: MWCO,
nominal molecular weight cut-off of the microdialysis membrane. Originally
published by Shannon et al. (2013) in J Pharmacokinet Pharmacodyn 40:
343–458 under a Creative Commons Attribution Licence.
of outcome (Timofeev et al., 2011a). Compared with normal
brain, the course of the glycolytic pathway from glucose to lactate
differs after injury, with in some cases an increase in the pro-
portion of lactate produced via diversion of glucose-6-phosphate
through the pentose phosphate pathway (PPP), also termed hex-
ose monophosphate shunt, compared with direct glycolysis that
even so remains the major route (Bartnik et al., 2005, 2007;
Dusick et al., 2007; Jalloh et al., 2013).
Measurement of Glycolysis and Lactate
Glycolysis is a multi-stage pathway with many facets, and there
are various biochemical approaches to measuring glycolysis.
Microdialysis is a tool for monitoring cerebral metabolism. Mon-
itoring of severe TBI patients in neurocritical care may include
intracranial pressure, brain tissue oxygen and extracellular chem-
istry using microdialysis. The latter possesses a semi-permeable
membrane that is continuously perfused with fluid, allowing
molecules to diffuse across the membrane, to and from the
brain’s extracellular space. Clinically, the catheter is perfused
with a physiological salt solution and the returning fluid (micro-
dialysate) is analyzed at the bedside utilizing automated enzy-
matic colorimetric assays tomeasure endogenous glucose, lactate,
pyruvate, glutamate, and glycerol. In this way microdialysis has
been used to monitor glucose delivery to the brain and, using L/P
ratio, as a marker of the balance between “aerobic” (referring to
TCA cycle) and “anaerobic” metabolism (referring to glycolysis
culminating in lactate). A schematic diagram of the microdialysis
catheter is shown in Figure 1.
In the laboratory, a classic method of measuring “true gly-
colysis” (the Embden-Meyerhof-Parnas pathway, also termed the
Embden-Meyerhof pathway), is to measure radioactive water
produced from [5-3H]-glucose, used originally in ex vivo organ
Frontiers in Neuroscience | www.frontiersin.org 2 April 2015 | Volume 9 | Article 112
Carpenter et al. Glycolysis and lactate in TBI
(heart) perfusion (Neely et al., 1972) and more recently in vitro
in cell cultures (e.g., De Bock et al., 2013). A limitation of this
assay is that it does not measure conversion of glucose all the way
through to pyruvate, and since it uses long-lived radioactivity in
the form of tritium it is unsuitable for use in humans. A possi-
ble alternative would be to adapt the method by using the stable
isotope deuterium in place of radioactive tritium and quantify
the deuterated water by mass spectrometry. However, this would
require a specialized type of mass spectrometry that is not widely
available.
Besides the above, there are various other techniques and
instrumentation for measuring aspects of glycolysis in the labora-
tory, reviewed recently (TeSlaa and Teitell, 2014). These are per-
formed under controlled conditions, often in cell cultures with
specific inhibitors to tie down particular components of biochem-
istry, although general principles such as measurement in vitro of
extracellular levels of lactate, glucose and concentration of oxy-
gen are also shared with neurocritical care monitoring in vivo.
We have already mentioned microdialysis (above) for measuring
brain extracellular glucose, lactate etc., and brain tissue oxygen
(PbtO2) can be measured alongside using an intracranial oxy-
gen sensor (Timofeev et al., 2011b; Shannon et al., 2013; Jalloh
et al., 2015). Extracellular acidification measurement, employed
in vitro, has also been performed in patients using the Neu-
rotrend sensor to measure brain extracellular pH, although no
further measurements are possible as the manufacturer (Diamet-
rics, Buckinghamshire, UK) has discontinued this sensor and no
alternative clinically approved intracranial pH sensor currently
exists (Timofeev et al., 2013). Another glycolysis-related mea-
surement is uptake of 18F-deoxyglucose (FDG) by cells. FDG is
a glucose analog that becomes phosphorylated inside the cells
and retained without further metabolism. FDG is more often
employed in patients (as opposed to cell cultures), with clinical
imaging by positron emission tomography (PET) as exemplified
below.
Various studies of FDG-PET have been carried out in TBI
patients, for example (Vespa et al., 2005; Hutchinson et al., 2009).
Established computation methods allow cerebral metabolic rate
of glucose (CMRglc, expressed in units ofµmol/100 g tissue/min)
to be determined for the desired regions of interest (ROIs), e.g.,
a 2 cm ROI around the microdialysis catheter tip (Hutchinson
et al., 2009). While FDG-PET cannot distinguish glycolysis from
TCA cycle metabolism, the use of microdialysis provides infor-
mation on extracellular lactate, pyruvate and glucose concentra-
tions and allows inferences to be made. A combined FDG-PET
and microdialysis study showed significant positive correlations
of CMRglc with lactate and pyruvate concentrations, no relation-
ship between CMRglc and L/P ratio, and a weak inverse trend
for CMRglc with glucose concentrations in the microdialysates
(Figure 2) (Hutchinson et al., 2009). The study concluded (with
the caveat of being a small study in 17 patients) that in TBI brain,
an increase in glucose metabolism leads to increases in both
lactate and pyruvate, as opposed to a shift toward “anaerobic”
metabolism (Hutchinson et al., 2009). Only 2 of the 17 patients in
this study showed very high L/P ratio exceeding 40 (Hutchinson
et al., 2009), a state known as metabolic crisis. In a different study
of microdialysis combined with PET (FDG and triple oxygen), a
higher proportion (7 out of 19) of patients showed metabolic cri-
sis (L/P ratio >40) though only a single patient showed regional
ischemia (Vespa et al., 2005). Unlike (Hutchinson et al., 2009),
there was no correlation between microdialysis parameters and
regional CMRglc (Vespa et al., 2005). The apparent disparity
between the two studies’ results was suggested to have stemmed
at least partly from the different proportions of metabolic crisis
patients (Hutchinson et al., 2009).
As diffusion across the microdialysis membrane is bi-
directional, microdialysis can also be used to deliver molecules
(“retrodialysis” e.g., 13C-labeled substrates), thereby micro-
dosing a region of interest around the catheter tip, whilst simul-
taneously collecting the products in the emerging microdialysate,
for subsequent NMR analysis. In this way, we have infused
1,2-13C2 glucose into TBI patients’ brains via the microdialysis
catheter to compare production of glycolytic 2,3-13C2 lactate vs.
PPP-derived 3-13C lactate (Jalloh et al., 2015). This study was car-
ried out with brain tissue oxygen (PbtO2) measured simultane-
ously in the vicinity of the microdialysis catheter, shedding light
on the relationship of local oxygen concentration to glycolytic-
and PPP- generated lactate. Also, the 13C-labeling enabled newly
synthesized lactate to be distinguished from “old” lactate, a differ-
entiation otherwise impossible without labeling. The findings of
the study (Jalloh et al., 2015) are discussed in the section enti-
tled “Origins of lactate in brain,” below. We have also shown
that infusion of 3-13C lactate or 2-13C acetate into the brains of
TBI patients via the microdialysis catheter produced 13C signals
for glutamine C4, C3, and C2 in the emerging microdialysates
(analyzed by NMR), indicating TCA cycle operation followed
by conversion of glutamate to glutamine (see Figure 3 and sec-
tion entitled “Brain utilization of lactate,” below) (Gallagher et al.,
2009). Microdialysis can thus be used to manipulate the imme-
diate microenvironment around the catheter by adding chosen
metabolic substrates that enter the relevant biochemical path-
ways at different stages allowing specific stages of the process to
be investigated.
Brain TCA cycle flux in humans has been measured employ-
ing in vivo magnetic resonance spectroscopy (MRS) using 13C-
labeled glucose (typically 1-13C glucose or 1,6-13C2 glucose)
(Rothman et al., 2011). The TCA cycle flux is calculated by kinetic
modeling of 13C labeling in glutamine and glutamate in brain
measured by MRS, during 13C labeled glucose intravenous infu-
sion. The technique has been mostly applied to healthy volun-
teers. A few in vivoMRS studies of 13C-labeling have been carried
out in patients with various pathologies, but the technique has
not yet been applied to the severe TBI field. Only a few centers
worldwide have neurocritical care units adjacent to MRI scan-
ners equipped for MRS and the expertise to support fully venti-
lated severe TBI patients through the procedure, and moreover,
13C measurement of TCA cycle is itself a highly specialized area
within the in vivo MRS field. In vivo brain MRS studies of 13C
labeling are extendable to other intravenously administered sub-
strates; for example 13C acetate has been used (Lebon et al., 2002),
and in vivoMRS has been used to examine 13C lactate utilization
in the TCA cycle, by measuring 13C labeling kinetics in glutamate
and glutamine in healthy volunteers (Boumezbeur et al., 2010).
Reviewing the latter study, Rothman et al. (2011) commented as
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FIGURE 2 | FDG-PET measurement of CMRglc and its relationship
to brain microdialysate composition: (A–C) FDG-PET CMRglc
map demonstrating relatively high FDG uptake at sites of injury,
in contrast to less injured areas of the brain. (A) Computed
tomography (CT) scan showing gold tip of microdialysis catheter
(indicated by arrow). (B) Co-registered FDG-PET CMRglc map showing
high FDG uptake at sites of injury. (C) Overlay of CT and co-registered
CMRglc map, showing microdialysis catheter tip location (arrow). (D–F)
Graphs illustrating relationships by linear regression (for 22 ROIs in 17
TBI patients) between FDG-PET derived CMRglc and the microdialysis
parameters measured during the scan (D) lactate, (E) pyruvate, (F)
lactate/pyruvate (L/P) ratio, and (G) glucose. For the linear regressions
in (D–G), corresponding values of p (ANOVA) are <0.0001, <0.0001,
0.74, and 0.48, respectively. Data-points from catheters at craniotomy
sites (four patients) are differentiated by gray triangles. Data-points
from a second FDG-PET scan (one patient) are differentiated by gray
diamonds. All other data-points are depicted as black circles (catheters
inserted via cranial access device). Linear regressions presented on the
graphs are for the entire (combined black plus gray symbols) dataset
consisting of all 22 ROIs. Originally published by Hutchinson et al.
(2009) in Acta Neurochir (Wien) 151: 51–61, and reproduced with kind
permission of Springer Science+Business Media.
follows. “Relative consumption of plasma lactate between neu-
rons and astrocytes is similar to that of glucose (Boumezbeur
et al., 2010). The calculation of the lactate metabolic capacity is in
good agreement with recent AV difference studies using isotopi-
cally labeled lactate as a tracer, further confirming the potential
importance of plasma lactate as a substrate for brain metabolism
(van Hall et al., 2009).”
More readily achievable than 13C in vivo MRS measurements
of TCA cycle flux are 1H in vivo MRS measurements of endoge-
nous molecules. 1H in vivo MRS in TBI clinically in patients
(Figure 4) (Marino et al., 2007) have shown that the most abun-
dant signal is N-acetylaspartate (NAA), a mitochondrial marker.
As absolute quantification is difficult, NAA is often expressed
as a ratio to creatine, or sometimes to choline (Marino et al.,
2007; Maddock and Buonocore, 2012). While lactate is abundant
extracellularly (at millimol/L concentrations readily measurable
on microdialysis), it is, in contrast, much less evident on 1H
in vivo MRS of normal or TBI brain. Moreover, depending on
the choice of echo time for MRS, these small lactate signals can
virtually disappear or appear inverted. Lactate elevation can be
seen on 1H in vivoMRS in pathological states, e.g., in tumors. In
TBI brain, lactate elevation can be seen on 1H MRS in some but
not all instances (Marino et al., 2007).
Another in vivo modality is 31P MRS, which can inform on
ATP in tissues, including brain, by measuring the phosphocre-
atine/ATP ratio and inorganic phosphate/ATP ratio (Garnett
et al., 2001) or by 31P magnetization-transfer methods (Befroy
et al., 2012). 31P has a natural abundance of 100% of all phos-
phorus atoms. While ATP is produced at a much higher yield
(per molecule of glucose) by the combination of glycolysis plus
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FIGURE 3 | Upper panel: (a) Example of 13C NMR spectrum of brain
microdialysate from a TBI patient, who received perfusion with 2-13C
acetate (4mM) by a microdialysis catheter via a craniotomy (CTO);
red stars indicate 13C signals for glutamine C4, C3, and C2 indicating
metabolism via TCA cycle. (b) 13C NMR spectrum of the 2-13C acetate
substrate solution prior to perfusing. (c) 13C NMR spectrum of brain
microdialysate from an unlabeled patient whose microdialysis catheter was
(Continued)
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FIGURE 3 | Continued
perfused with plain perfusion fluid without labeled substrate. Lower panel:
(a,b) Examples of 13C NMR spectra of brain microdialysates from a TBI
patient, who received perfusion with 3-13C lactate (4mM) by microdialysis
catheters via a craniotomy (CTO); red stars indicate 13C signals for glutamine
C4, C3, and C2 indicating metabolism via TCA cycle. (c) 13C NMR spectrum
of the 3-13C lactate substrate solution prior to perfusing. (d) 13C NMR
spectrum of brain microdialysate from an unlabeled patient [as in Upper
panel (c)]. Originally published by Gallagher et al. (2009) in Brain 132:
2839–2849, and reproduced with permission of Oxford Journals.
FIGURE 4 | Proton magnetic resonance spectra and conventional
magnetic resonance images showing the volume of interest for
spectroscopic imaging of a normal control (left panel), Patient 1
(central panel), and Patient 8 (right panel) with traumatic brain
injury (TBI). On conventional MRI, Patient 1 shows a focal hematoma in
the frontal left hemisphere and patient 8 shows diffuse MRI abnormalities.
Spectra show decreases of N-acetylaspartate (NAA) and increases of
choline (Cho) and lactate (La) in patients with TBI (a and b in central and
right panels) with respect to the normal control (a in left panel). The
spectra of Patient 1 (central panel) show more pronounced metabolic
abnormalities than those of Patient 8 (right panel), despite the fact that
Patient 8 showed markedly more abnormalities on conventional MRI. In
the spectra of Patient 1 (central panel), metabolic abnormalities are clearly
evident in the normal appearing brain. Finally, in Patient 1, voxels inside
the focal hematoma (c in central panel) were excluded to avoid the
artifacts that could be derived by the cerebral haemorrhagic contusion. Cr,
creatine. Reproduced from J Neurol Neurosurg Psychiatry, Marino et al.
78: 501–507 (2007) with permission from BMJ Publishing Group Ltd.
mitochondrial metabolism than by glycolysis alone, the latter is
thought to represent a quick source of ATP under stress-response
conditions such as TBI. A combination of modalities is needed
in order to differentiate between glycolysis and mitochondrial
metabolism as sources of ATP in brain.
Origins of Lactate in Brain
The majority of lactate in the brain is regarded as “glycolytic,”
originating from glucose metabolism in situ, by the Embden-
Meyerhof pathway, to pyruvate, followed by conversion of pyru-
vate to lactate by the action of lactate dehydrogenase (LDH).
Other routes to brain lactate, including synthesis via the PPP and
uptake of lactate from the circulation, are discussed below.
There is some disparity in nomenclature in the brain
metabolism literature, which undoubtedly adds confusion for any
non-biochemist readers, or even for biochemists unfamiliar with
the brain injury field. In the brain injury literature, glycolysis
culminating in lactate is often termed “anaerobic metabolism,”
though often without supporting evidence regarding the oxy-
gen status in the tissue concerned. In old studies brain injury
was often associated with hypoxia/ischemia (real or assumed),
although more recently advances in neurocritical care mean that
overt hypoxia/ischemia is usually avoided. Even so, microvascu-
lar ischemia appears to exist in some cases (Newcombe et al.,
2013), as do episodes of hypoxia (Timofeev et al., 2011b). We
regard hypoxia as PbtO2 <20mmHg, with severe hypoxia as
PbtO2 <10mmHg.
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High brain lactate concentrations may result from
mitochondrial dysfunction forcing cells to rely on glycoly-
sis (Embden-Meyerhof pathway) to generate ATP. Without
functional mitochondrial electron transport chains (ETC) and
shuttles, the conversion (mediated by LDH) of pyruvate to lactate
is necessary to recycle NADH to NAD+ to enable glycolysis
to continue. Hypoxia prevents mitochondria from functioning
properly. Since molecular oxygen (O2) is the terminal elec-
tron acceptor of the ETC, adequate O2 presence is vital for
mitochondrial function. However, mitochondria may become
dysfunctional even in the presence of O2, for instance if any of the
ETC components are damaged, or if the TCA cycle (which feeds
the ETC) is compromised, or if the mitochondrial membranes
become leaky. The concentration of lactate in the brain depends
not only on lactate production but also lactate consumption. We
have previously commented, “Low extracellular lactate levels,
associated with better outcomes (Timofeev et al., 2011a), might
be because astrocytic glycolysis-derived lactate is being efficiently
taken up by neurons and utilized via the TCA cycle (Gallagher
et al., 2009). Conversely, high extracellular lactate may result if
neurons are too damaged to efficiently utilize the lactate being
produced by astrocytes, i.e., uncoupling of neuronal and glial
metabolism” (Carpenter et al., 2014).
In classic biochemical terms, “glycolysis” is the Embden-
Meyerhof pathway from glucose to pyruvate, whereas the pyru-
vate to lactate step is a subsequent conversion that is not part of
glycolysis proper. Pyruvate does not necessarily produce lactate,
as pyruvate can be converted into acetyl CoA and thence enter the
TCA cycle. Also, lactate can be converted to pyruvate, and thence
to acetyl CoA and the TCA cycle (see Section entitled “Utilization
of lactate,” below). The description “glycolytic” is often loosely
applied to cells or tissues that produce abundant lactate, e.g.,
injured regions of brain or tumors, and these cells/tissues also
may have apparently elevated PPP as well as high glycolysis. In
tumors, and especially in cancer cell lines in vitro, it has long been
recognized that the high glycolysis often occurs despite a ready
supply of oxygen, a phenomenon known as the Warburg effect
(Warburg, 1956), often termed “aerobic glycolysis” in the tumor
literature (Bensinger and Christofk, 2012). In a study of 24 TBI
patients, Sala et al. (2013) judged that elevations in brain extra-
cellular lactate were predominantly “glycolytic,” with “hypoxic”
lactate elevation in a minority. These authors stated their criteria
for “hypoxic lactate” as microdialysate lactate >4mmol/L with
PbtO2 <20mmHg, and “glycolytic lactate” as microdialysate lac-
tate >4mmol/L with microdialysate pyruvate >119mmol/L. It
is relevant to comment that the actual origins of the lactate were
not determined in this study. Therefore, the brain extracellular
lactate detected may have included a minor portion arising via
the PPP rather than direct glycolysis, and moreover some of the
lactate may have entered the brain from the circulation; see below
for further information. Results from CT perfusion (with iohexol
contrast agent) available for a subset of (16 out of 24) patients in
the study by Sala et al. suggested that “glycolytic” lactate was asso-
ciated with hyperaemic brain perfusion, and “hypoxic” lactate
with “diffuse oligaemia” (Sala et al., 2013).
Relevant to the balance between lactate and pyruvate is the
nature of the LDH enzyme. Two distinct subunits are combined
to form the five tetrameric isoenzymes of LDH. Subunit LDH1
(“heart type,” found in neurons) preferentially drives lactate to
pyruvate, while subunit LDH5 (“muscle type”) is present in
“glycolytic tissues” and in both neurons and astrocytes, and
preferentially drives pyruvate to lactate (Bittar et al., 1996).
The PPP is a complex detour starting from glucose-6-
phosphate (hence its alternative name “hexose monophos-
phate shunt”) bypassing some of the steps of glycolysis in the
metabolism of glucose, and its key features have been summa-
rized as follows by Jalloh et al. (2015). “The key enzyme for the
PPP, glucose-6-phosphate dehydrogenase, which is responsible
for the rate-limiting step, is present in most tissues and cell types,
and is regarded as a “housekeeping” enzyme (Pandolfi et al., 1995;
Riganti et al., 2012). The PPP does not consume or produce ATP
and does not require molecular oxygen. In the early “oxidative
phase” of the PPP, the first carbon of the glucose skeleton is lost
as carbon dioxide, and nicotinamide adenine dinucleotide phos-
phate (NADP+) is converted to NADPH. The latter participates
in reductive biosynthetic reactions, such as lipid synthesis and
in producing the reduced form of glutathione and thioredoxin
which are cofactors for glutathione peroxidase and peroxiredox-
ins respectively, both of which scavenge hydroperoxides, thereby
combatting oxidative stress. Among the many intermediates of
the later “non-oxidative” phase of the PPP is ribose 5-phosphate,
used for nucleic acid synthesis. PPP activity after TBI has been
suggested to play a protective role, promoting synthesis of nucleic
acids and fatty acids for tissue repair and combatting oxidative
stress (Ben-Yoseph et al., 1996; Bartnik et al., 2005).”
Microdialysis perfusion with 1,2-13C2 glucose, in TBI patients’
brains, and, for comparison, in “normal” brain in non-TBI
patients, with high-resolution 13C NMR analysis of the emerg-
ing microdialysates, has enabled comparison of lactate produc-
tion by glycolysis (evidenced by 2,3-13C2 lactate), and the PPP
(evidenced by 3-13C lactate) (Jalloh et al., 2015). Doubly labeled
lactate (with 13C next to 13C) produces characteristic doublet sig-
nals on 13CNMR, distinct from singlets due to single 13C labeling
(13C next to 12C). A schematic of the biosynthetic pathway label-
ing patterns is shown in Figure 5 (Carpenter et al., 2014; Jalloh
et al., 2015), and illustrative examples of 13C NMR spectra in
Figure 6 (Jalloh et al., 2015). The natural abundance of 13C is
1.1% of all carbon atoms, so the probability of two endogenous
13C atoms occurring next to each other naturally is 1.1× 1.1%=
0.01%, thus the doublet signature, for doubly 13C labeled lactate,
is essentially free from background. The singly 13C labeled lactate
results were expressed after background-subtraction of the nat-
ural lactate’s contribution to 13C NMR singlet signals. Glycolysis
was always the major source of lactate and the PPP the minor
source. The conclusions were as follows (Jalloh et al., 2015), and
the graphs (Figures 7, 8) are from the same paper. “The minor
pathway, PPP-derived lactate production, was statistically not
significantly different in the TBI brain than in normal brain.
However, several of the TBI individuals showed PPP-derived
lactate elevation above the range observed in the normal brain
(Figure 7). There was a shift in glucose metabolism from glycol-
ysis to PPP with decreasing brain tissue oxygen (PbtO2) concen-
trations (Figure 8). The findings raise interesting questions about
the roles of the PPP and glycolysis after TBI, andwhether they can
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FIGURE 5 | Simplified schematic of steps in glycolysis and the
pentose phosphate pathway (PPP), showing 13C labeling
patterns resulting from 1,2-13C2 glucose substrate. Red fills
indicate 13C atoms. Abbreviations: Glc-6-P, glucose-6-phosphate;
6PGL, 6-phosphogluconolactone; F6P, fructose-6-phosphate; G3P,
glyceraldehyde-3-phosphate; PYR, pyruvate. Originally published by
Carpenter et al. (2014) in Eur J Pharm Sci 57: 87–97 under a
Creative Commons Attribution Licence.
bemanipulated to enhance the potentially reparative and antioxi-
dant role of the PPP and achieve a better outcome for the patient.
The 13Cmethodology developed here provides a means of distin-
guishing recently synthesized lactate and its biosynthetic origin,
and at the same time measuring local oxygen tension alongside.
13C-labeled microdialysis with 1,2-13C2 glucose as substrate may
thus find a methodological role in studies of hyperoxia or strate-
gies to optimize perfusion and mitochondrial function. This is
the first time that a comparison between glycolysis and the PPP
has been carried out directly in the human brain.”
Studies in adult rats and brain slices suggested that the PPP
increased after hypoxia (Domanska-Janik, 1988). Contrastingly,
other researchers found that, in neonatal rats, the PPP decreased
after hypoxia-ischemia, suggesting that inability to upregulate the
PPP may render neonatal brain vulnerable to oxidative stress
(Brekke et al., 2014).
Although the shared gateway into both the Embden-Meyerhof
pathway and the PPP is via the action of hexokinase (HK) con-
verting glucose to glucose-6-phosphate (G6P), there are several
isoforms of that enzyme. HKI (dubbed “the brain HK”) seems
to predestine G6P for subsequent processing via the Embden-
Meyerhof pathway, while HKII (“the muscle HK”) has a more
complex role and under some circumstances seems to predispose
toward the PPP. There is evidence to suggest HK1 being located
bound to mitochondria. The interaction of HKs with mitochon-
dria is not static, but is regulated by factors such as glucose, G-6-P
and kinases such as protein kinase B (PKB, also known as Akt)
and glycogen synthase kinase 3 (GSK-3). Accordingly, HKII has
been suggested to translocate between the cytosol, where it chan-
nels G6P into the PPP, and binding to mitochondria, where it
predisposes G6P to “glycolysis and oxidative phosphorylation”
(John et al., 2011). It has been suggested that shifts in expression
(and/or activity) between HKI and HKII may be a contributing
factor (e.g., in injury or disease) to changes in the balance between
the Embden-Meyerhof pathway and the PPP (John et al., 2011).
Glucose-6-phosphate dehydrogenase (G6PD, also known as
G6PDH), the enzyme responsible for the rate-limiting step of
the PPP, is known to exhibit many gene mutations, some of
which are manifest as various degrees of G6PD enzyme defi-
ciency (Notaro et al., 2000; Cappellini and Fiorelli, 2008). The
G6PD gene is on the X-chromosome, and has long been rec-
ognized in the context of the phenomenon of the mosaic of X-
chromosome inactivation in females (Beutler et al., 1962), termed
Lyon’s Hypothesis or Law (Lyon, 1961; Gendrel and Heard, 2011;
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FIGURE 6 | Illustrative examples of 13C NMR spectra for
microdialysates from patients who received perfusion with 1,2-13C2
glucose (4mmol/L): TBI brain (uppermost two spectra, 24-h
perfusion), “normal” brain (third spectrum, 24-h perfusion), and
muscle (bottom spectrum, 8-h perfusion). An example of brain
microdialysate from an unlabeled TBI patient with plain (unsupplemented)
perfusion fluid is shown for comparison (fourth spectrum). Examples of
expansion of the lactate C3 signal are shown for TBI brain and “normal”
brain. Red stars indicate lactate C3 doublet (due to glycolytic 2,3-13C2
lactate) and green stars indicate C3 singlet (due to pentose phosphate
pathway-derived 3-13C lactate plus endogenous lactate). Glucose (Glc),
lactate (Lac), 4,4-dimethyl-4-silapentane-1-sulfonate sodium salt (DSS, the
internal reference standard). Spectra were run from −20 to +250 p.p.m. The
main reference DSS signal at 0 p.p.m. is not shown in the range illustrated.
Originally published by Jalloh et al. (2015) in J Cereb Blood Flow Metab 35:
111–120, and reproduced with permission of Nature Publishing Group.
Harper, 2011). In female embryo early development, inactivation
occurs randomly of one of the two X-chromosomes in each cell,
then tissues and organs develop as mosaics consisting of clonal
patches of cells that maintain their original inactivation state dur-
ing subsequent cell divisions. G6PD can be inhibited by dehy-
droepiandrosterone (DHEA) (Rodriguez-Rodriguez et al., 2013).
DHEA, a neurosteroid, is synthesized in brain, and also outside
of brain (mainly by adrenal glands). DHEA is considered neuro-
protective, and, in human brain tissue, there was a tendency for
lower DHEA levels in subjects with Alzheimer’s disease than in
non-dementia similarly-aged controls (Schumacher et al., 2003).
Endogenous DHEA levels are regarded as declining with age, and
highest in males and lower in females, based on circulating levels
which show individual variations and pathology-related varia-
tions (Samaras et al., 2013). DHEA in brain tissue is less well-
understood. The above factors regarding G6PD andDHEAmight
thus contribute to variability in the PPP vs. glycolysis as sources
of lactate.
Another source of lactate in the brain, besides production in
situ from glucose via glycolysis (major pathway) and PPP (minor
pathway) is uptake of lactate from the circulation (Ide et al.,
2000; Overgaard et al., 2012). The brain shows periods of net
uptake and net export of lactate. This has been studied by arte-
riovenous (AV) difference in TBI patients by Jalloh et al. (2013).
Their conclusions were as follows (Jalloh et al., 2013). “Our find-
ings suggest that the injured brain takes up lactate, which can be
oxidatively metabolized (Gallagher et al., 2009). Lactate uptake
occurs despite relatively high brain lactate levels after TBI sug-
gesting up-regulation of MCT transporters. Glucose delivery to
brain cells is maintained during periods of lactate uptake. Hence,
lactate uptake may reflect an adaptive response to the increased
energy demands and change in metabolic priorities of the injured
brain. The injured brain’s capacity to use endogenous lactate as
an alternative fuel implies that exogenous lactate may be thera-
peutic in TBI patients. Accordingly, rats given intravenous lactate
after fluid percussion injury performed better than those given
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FIGURE 7 | Microdialysate NMRmeasurements of 13C labeling: results
from perfusion for 24-h- (brain: TBI or “normal”) or 8-h perfusion
(muscle) with 1,2-13C2glucose (4mmol/L). Red asterisks denote P < 0.01
for TBI vs. “normal” brain (Mann–Whitney); other comparisons asterisked in
black denote P < 0.05. Individual data points are shown by× symbols.
Number of patients: 15 TBI, six “normal” brain, and four muscle. Originally
published by Jalloh et al. (2015) in J Cereb Blood Flow Metab 35: 111–120,
and reproduced with permission of Nature Publishing Group.
saline (Rice et al., 2002; Holloway et al., 2007). Glycemic con-
trol of neurocritical care patients is necessary to avoid both hypo-
and hyperglycaemia, although tight glycaemic control may be too
restrictive for optimal cerebral metabolism and less rigid control
may be preferable (Kramer et al., 2012). Lactate administration
may have a role in supporting energy metabolism in this context.
Ongoing and future clinical studies will elucidate whether lactate
administration improves outcomes.”
A possible contribution to lactate in brain is via the TCA cycle
(Cruz and Cerdan, 1999; Tyson et al., 2003; Sonnewald, 2014).
The TCA cycle intermediates malate and oxaloacetate (OAA)
can be converted to pyruvate by the action of malic enzyme;
also OAA can be converted by the action of phosphoenolpyru-
vate carboxykinase (PEPCK) plus pyruvate kinase (PK) to pyru-
vate, then LDH can convert pyruvate to lactate. Anaplerosis (i.e.,
topping-up) of TCA cycle intermediates is coupled to cataplerosis
(i.e., spin-out) from the TCA cycle, and Sonnewald has recently
hypothesized, “cataplerosis in the brain is achieved by export-
ing the lactate generated from TCA cycle intermediates into the
blood and perivascular area.... This shifts the generally accepted
paradigm of lactate generation as simply derived from glycolysis
to that of oxidation and might present an alternative explanation
for aerobic glycolysis” (Sonnewald, 2014). Whether this is a sig-
nificant route of lactate production in human TBI brain is not (to
our knowledge) reported in the literature.
Utilization of Lactate in TBI
While glucose is recognized as the primary energy substrate in
most organs, recent evidence suggests that the situation in the
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FIGURE 8 | Relationships in TBI brain for glycolytic lactate and pentose
phosphate pathway (PPP)-derived lactate vs. PbtO2. Concentrations of
glycolytic 2,3-13C2 lactate (upper panel) and PPP-derived 3-
13C lactate
(middle panel) plotted vs. PbtO2. Lower panel: ratio (%) of PPP-derived 3-
13C
lactate to glycolytic 2,3-13C2 lactate, plotted vs. PbtO2. Each data point
represents the results of NMR analysis of the combined contents of 24× 1 h of
microdialysate collection vials from one microdialysis catheter, plotted against
the corresponding PbtO2 concentration expressed in mmHg, measured using
a Licox oxygen probe placed alongside the microdialysis catheter in the brain.
Lines are fitted by linear regression (statistics shown are Pearson’s correlation
coefficient r and analysis of variance P–value). Data are from 13 TBI patients.
Four of these thirteen had a second period of monitoring, making 17 data
points in total for each correlation. Originally published by Jalloh et al. (2015) in
J Cereb Blood Flow Metab 35: 111–120, and reproduced with permission of
Nature Publishing Group.
brain is considerably more complex, particularly in relation to
the main cell types. Traditionally it has been believed that both
glia and neurons metabolize glucose as the preferred substrate
via glycolysis to pyruvate, which is converted to acetyl CoA
and enters the TCA cycle resulting in the generation of ATP
by oxidative phosphorylation. Recent evidence suggests, how-
ever, that the neurons may utilize lactate (classically perceived
as a waste product) as an energy substrate. Figure 9 outlines a
scheme of metabolic trafficking between astrocytes and neurons
(Gallagher et al., 2009). Glucose (Glc) from the vasculature is
metabolized to lactate (Lac) in astrocytes, exported into the extra-
cellular fluid, taken up by neurons and processed (via pyruvate
and acetate) by the TCA cycle. This spins off glutamate (Glt),
which is released and then taken up by astrocytes, which con-
vert it to glutamine (Gln), which is released into the extracellular
fluid and taken up by neurons, which re-convert it to glutamate
(Gallagher et al., 2009). This theory, which has become known as
the astrocyte-neuron lactate shuttle (ANLS) hypothesis was pro-
posed by Pellerin and Magistretti (1994) as a result of in vitro
studies and has been later supported by studies in animals, (e.g.,
Tyson et al., 2003). Moreover, our recent microdialysis studies
using 13C-labeling have demonstrated that the injured human
brain can metabolize lactate via the TCA cycle (Gallagher et al.,
2009). We suggested that low extracellular lactate levels, with
better outcomes, might be because astrocytic glycolysis-derived
lactate is being efficiently taken up by neurons and utilized via
the TCA cycle (Gallagher et al., 2009). Conversely, where neu-
rons are too damaged to utilize the lactate produced from glucose
by astrocytes, i.e., uncoupling of neuronal and glial metabolism,
high extracellular levels of lactate would accumulate, with poor
outcome (Carpenter et al., 2014).
Although the ANLS hypothesis is still somewhat controver-
sial, in recent years the concept of lactate as a brain energy sub-
strate has been extended even further by Schurr in the postulation
that lactate (rather than pyruvate) may be the true substrate for
mitochondrial respiration (Schurr, 2006). In Schurr’s postulated
scheme, the glycolytic route in the cytosol, from glucose to pyru-
vate then by LDH-mediated conversion to lactate, is followed by
uptake of lactate by a monocarboxylate transporter (MCT) in the
mitochondrial outer membrane, then by conversion of lactate
to pyruvate (by LDH1?) in the mitochondrial inner membrane
(Schurr, 2006). The rest of the biochemical pathway of mitochon-
drial respiration (pyruvate to acetate CoA, TCA cycle, ETC and
ATP synthesis) then follows on.
More recent studies of the significance of lactate led Suzuki
et al. to propose, “astrocyte-neuron lactate transport is essen-
tial for long term synaptic plasticity, long-term memory, and
its underlying molecular and synaptic changes” (Suzuki et al.,
2011). Lactate transport may thus have important implications
for pathologies with cognitive deficits. Very recently, Galow et al.
showed that gamma oscillations, required for complex neuronal
processing, can be fuelled by energy-rich substrates, most effec-
tively by high concentrations of glucose, but also, to a some-
what lower degree, by high concentrations of lactate or pyruvate
(Galow et al., 2014).
A recent study by Bouzat et al. showed evidence for beneficial
effects (judged by surrogate markers) resulting from intravenous
lactate administration in 15 TBI patients (Bouzat et al., 2014). A
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FIGURE 9 | Glucose (Glc) from the vasculature is metabolized to
lactate (Lac) in astrocytes, exported into the extracellular fluid, taken
up by neurons and processed [via pyruvate (Pyr) and acetate (Ac)] by
the TCA cycle. This spins off glutamate (Glt), which is released and then
taken up by astrocytes, which convert it to glutamine (Gln), which is released
into the extracellular fluid and taken up by neurons, which re-convert it to
glutamate. For details of the relevant membrane transporters (see Chih and
Roberts, 2003; Gallagher et al., 2009; Pellerin and Magistretti, 2012). Besides
Lac production in situ from Glc, Lac may also be taken up from the circulation,
(see Ide et al., 2000; Overgaard et al., 2012; Jalloh et al., 2013). For typical
concentrations of the above species and PbtO2 (see Gallagher et al., 2009;
Timofeev et al., 2011a,b). Originally published by Gallagher et al. (2009) in
Brain 132: 2839–2849, and reproduced with permission of Oxford Journals.
mixed effects linear regression model was used to evaluate the
results. The treatment caused increases in brain microdialysate
lactate (coefficient 0.47mmol/L, 95% confidence interval 0.31–
0.63mmol/L), pyruvate [13.1 (8.78–17.4) µmol/L], and glucose
[0.1 (0.04–0.16) mmol/L; all p < 0.01]. Reductions in brain
microdialysate glutamate [−0.95 (−1.94–0.06) mmol/L, p =
0.06] and ICP [−0.86 (−1.47–0.24) mmHg, p < 0.01] were also
observed (Bouzat et al., 2014). The lactate solution administered
was hypertonic, and it was not resolved how much of the appar-
ent benefit on ICP was due to this property or due to the actual
lactate itself.
An earlier study by Ichai et al. in TBI patients showed
that hyperosmolar sodium lactate solution (504mmol/L; 1100
mosm/L) given intravenously was more effective at lowering
ICP than a mannitol solution with an equivalent osmotic load
(1160mosm/L) (Ichai et al., 2009). Also, compared with saline
solution (0.9%), a 0.5 mol/L sodium lactate solution was more
effective at reducing the occurrence of raised ICP episodes in TBI
patients (Ichai et al., 2013). In a model of TBI–controlled corti-
cal impact (CCI) in rats–infusion of lactate (100mmol/L) showed
significantly improved cerebral blood flow (CBF), significantly
reduced lesion volume, and no significant difference in extracel-
lular glutamate concentration, when compared to CCI with saline
(0.9%) infusion control (Alessandri et al., 2012).
Furthermore, such studies of intravenous lactate and the con-
cept of the ANLS model have elicited controversy, and other
models have been proposed (Dienel, 2014). Much of the evidence
for the ANLS model is summarized in a review (Pellerin and
Magistretti, 2012). A recent kinetic modeling study in rats (using
non-radioactive 19F-FDG and 1,6-13C2 glucose) compared an
FIGURE 10 | Schematic depiction of two neuroenergetics models
under consideration to account for the 1:1 flux relationship between
increments in the rate of glutamate/glutamine cycling (Vcyc) and the
TCA cycle flux in neurons (VTCAn). (A) ANLS-type model (Model 1). (B)
Independent-type model (Model 2) in which neurons and astrocytes take up
and oxidize glucose according to their respective energy needs.
Phosphorylated glucose not oxidized within the cell may be effluxed as lactate,
VLac(efflux), which is shown by dashed lines. The results of this study in rat brain
suggested that neurons are capable of supporting a substantial fraction of
their substrate requirements by direct uptake and phosphorylation of glucose.
Originally published by Patel et al. (2014) in Proc Natl Acad Sci USA 111:
5385–5390, and reproduced with permission from Proc Natl Acad Sci USA.
ANLSmodel with an “independent” model in which neurons and
astrocytes take up and oxidize glucose according to their respec-
tive energy needs (Patel et al., 2014) (Figure 10). The results did
not support the ANLS astrocytic lactate production shuttling to
neurons to provide a major neuronal fuel, but instead favored the
“independent” model with neuronal glucose-derived pyruvate as
the major oxidative fuel for activated neurons (Patel et al., 2014).
Compatible with the conclusion of Patel et al. (2014)
is an in vitro study in mouse hippocampal slices with
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electrophysiological stimulation, in the presence of glucose com-
pared with pyruvate or, in some instances, lactate (Ivanov et al.,
2014). The prime measures were changes in NAD(P)H and tissue
oxygen, other measures being FAD, intracellular pH and Ca2+,
and ATP (Ivanov et al., 2014). Distinction of neuronal contri-
butions was achieved using inhibitors. These authors concluded,
“Our data do not support the hypothesis of a preferential utiliza-
tion of astrocyte-released lactate by neurons during network acti-
vation in slices–instead we show that during such activity glucose
is an effective energy substrate for both neurons and astrocytes”
(Ivanov et al., 2014).
Utilization of glucose but not lactate has been reported to cor-
relate with N-methyl-D-aspartate (NMDA)-induced neurotrans-
mission in mouse cerebellar neurons in vitro (Bak et al., 2009).
These authors have suggested, “the role of extracellular lactate
may be to support basal metabolism in neurons rather than neu-
rotransmission activity per se mandating a revision of how we
perceive the role of lactate in cerebral energy metabolism” (Bak
et al., 2009).
Whether the above findings in vivo in rats, and in vitro in
mouse brain slices andmouse neurons are relevant to human TBI
is as yet unknown.
While it is still debated (Dienel, 2014) whether or not lac-
tate is a “preferred fuel” (sparing glucose) after TBI or whether
brain energetics are improved as a result of intravenous lactate,
it is evident from 13C labeling studies that animal and human
brain (injured and non-injured) can utilize lactate via the TCA
cycle, judged by production of the appropriate 13C labeling pat-
terns in glutamate and/or glutamine (Tyson et al., 2003; Gal-
lagher et al., 2009; Boumezbeur et al., 2010). At face value, the
idea that intravenous administration of exogenous lactate may
be beneficial for TBI patients (Ichai et al., 2009, 2013; Bouzat
et al., 2014) seems to conflict with the association between high
(endogenous) brain extracellular lactate and poor outcome (Tim-
ofeev et al., 2011a). We have previously suggested that where
build-up of (endogenous) lactate occurs, this may be because the
neurons are too damaged to utilize it, which might explain the
association between high endogenous extracellular lactate and
poor outcome (Carpenter et al., 2014). A possible rationaliza-
tion of the apparently beneficial effect of lactate infusion (Ichai
et al., 2009, 2013; Bouzat et al., 2014) vs. the unfavorable associ-
ation of high endogenous lactate (Timofeev et al., 2011a) might
be that if PbtO2 is adequate, and if mitochondria are functioning,
then brain cells can use lactate as a feedstock, via conversion to
pyruvate and then acetate, for the TCA cycle and ultimately ATP
production.
Whether other “alternative fuels” (apart from lactate)might be
relevant in treating TBI is unknown. It has been suggested that
sodium pyruvate might be preferable to sodium lactate, partic-
ularly as pyruvate would bypass the redox step from lactate to
pyruvate (Dienel, 2014). However, pyruvate in solution is known
to self-react, forming various products including a dimer (para-
pyruvate) that can, at least under some circumstances, inhibit
alpha-ketoglutarate dehydrogenase, an enzyme in the TCA cycle
(Margolis and Coxon, 1986). An alternative form of pyruvate that
has been suggested is ethyl pyruvate which is reportedlymore sta-
ble in solution and has anti-inflammatory effects distinct from
sodium pyruvate (Fink, 2007).
Conclusions and Future Prospects
Understanding of the roles of glycolysis and lactate in the human
brain are continuing to evolve. From the original concept of
lactate as merely a waste product, with adverse associations in
injured brain, it is becoming increasingly recognized as a poten-
tial source of energy for the brain. Having the right balance
between glycolysis (and PPP) and mitochondrial metabolism
is vital. Controlling this balance is becoming recognized as a
therapeutic target in treating TBI patients during neurocritical
care. For interpreting the levels of brain extracellular lactate dur-
ing multimodality monitoring it is important to also take into
account the other parameters, including brain extracellular pyru-
vate and glucose levels, as well as circulating levels of glucose
and lactate in blood. Infusion and perfusion studies, and label-
ing with 13C with detection by ex vivoNMR or in vivoMRS, have
potential to shed further light on cerebral energy metabolism in
human brain and may help suggest strategies for improving TBI
treatment protocols for better clinical outcomes.
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